(R)-Melphalan

Summary

(R)-Melphalan (CHEMBL250892) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including ewing sarcoma and plasma cell myeloma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Chemistry: 305.2 Da · C13H18Cl2N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL250892
Name	(R)-Melphalan
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	20189
Molecular formula	C13H18Cl2N2O2
Molecular weight	305.2
InChIKey	SGDBTWWWUNNDEQ-GFCCVEGCSA-N

SMILES: C1=CC(=CC=C1C[C@H](C(=O)O)N)N(CCCl)CCCl

IUPAC name: (2R)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid

Also known as: (r)-melphalan, SID11111435, (R)-MELPHALAN

Patent coverage: 6,644 distinct patent families (23,925 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Thrombopoietin, Muscarinic acetylcholine receptor M1, Nuclear factor NF-kappa-B p105 subunit, Cytochrome P450 1A2, Cytochrome P450 3A4, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NFKB1	5.2	Potency	6310	nM	CHEMBL_ACT_3671922
NFKB1	5.2	Potency	6310	nM	CHEMBL_ACT_4585204
THPO	5.2	Potency	6310	nM	CHEMBL_ACT_4809381
THPO	5.2	Potency	6310	nM	CHEMBL_ACT_5070392
HIF1A	5	Potency	10000	nM	CHEMBL_ACT_4132675
HIF1A	5	Potency	10000	nM	CHEMBL_ACT_4519444
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_4949232
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_5078581
CYP3A4	5	AC50	10000	nM	CHEMBL_ACT_6009666

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Ewing sarcoma	3	MONDO:0012817	EFO:0000174
plasma cell myeloma	3	MONDO:0009693	EFO:0001378

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).